Skip to main content
Clinical Trials/NCT02847481
NCT02847481
Completed
Phase 1

A Pilot Study to Evaluate Fecal Microbiota Transplantation Engraftment in Irritable Bowel Syndrome

Beth Israel Deaconess Medical Center1 site in 1 country80 target enrollmentMay 2016

Overview

Phase
Phase 1
Intervention
fecal microbiota transplantation
Conditions
Irritable Bowel Syndrome
Sponsor
Beth Israel Deaconess Medical Center
Enrollment
80
Locations
1
Primary Endpoint
stable engraftment of donor microbiota
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

This is a randomized pilot study to characterize engraftment of a donor's microflora onto patients with Irritable Bowel Syndrome with diarrhea following fecal microbiota transplantation.

Registry
clinicaltrials.gov
Start Date
May 2016
End Date
August 5, 2018
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Anthony Lembo

Associate Professor of Medicine

Beth Israel Deaconess Medical Center

Eligibility Criteria

Inclusion Criteria

  • IBS with diarrhea

Exclusion Criteria

  • Not provided

Arms & Interventions

FMT after antibiotic pretreatment v1

fecal microbiota transplantation after antibiotic pretreatment

Intervention: fecal microbiota transplantation

fecal microbiota transplantation

fecal microbiota transplantation

Intervention: fecal microbiota transplantation

placebo fecal microbiota transplantation

placebo fecal microbiota transplantation

Intervention: placebo fecal microbiota transplantation

FMT after antibiotic pretreatment v1

fecal microbiota transplantation after antibiotic pretreatment

Intervention: FMT with antibiotic pre-treatment (v1)

FMT after antibiotic pretreatment v2

fecal microbiota transplantation after antibiotic pretreatment

Intervention: fecal microbiota transplantation

FMT after antibiotic pretreatment v2

fecal microbiota transplantation after antibiotic pretreatment

Intervention: FMT with antibiotic pre-treatment (v2)

Outcomes

Primary Outcomes

stable engraftment of donor microbiota

Time Frame: 10 weeks

Stable engraftment will be defined with the Jensen-Shannon Divergence (JSD) between the bacteria community measured in the donor and recipient. Engraftment scores will be defined by the ratio between the JSD in comparison between the recipient and donor and the recipient and other healthy donors not providing material for their FMT.

Study Sites (1)

Loading locations...

Similar Trials